Ryan Patrick Coll, Ph.D.
Department of Nuclear Medicine, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Instructor, Nuclear Medicine, Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Instructor, Research Faculty Appointment, Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2021 | Texas A&M University, College Station, Texas, US, Chemistry, Ph.D |
| 2014 | Wake Forest University, Winston-Salem, North Carolina, US, Chemistry with Biochemistry, BS |
Postgraduate Training
| 2022-2024 | Postdoctoral Fellow, Antibody-Based Radionuclide Theranostics, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2021-2021 | Postdoctoral Fellow, Dirhodium and Ruthenium Complex Design for Biological and Electrocatalytic Applications, Texas A&M University, College Station, Texas |
Experience & Service
Faculty Academic Appointments
Instructor, Research Faculty Appointment, Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - 2025
Editorial Activities
Guest Editor, Pharmaceuticals, 2024 - Present
Honors & Awards
| 2025 - Present | Top 2 Oral Presentation-Faculty Category, 3rd International Conference on Cancer Health Disparities |
| 2024 | Best Oral Presentation-Fellow/Post-Doc Category, 2nd International Conference on Cancer Health Disparities |
| 2024 | Trainee Travel Award, 2nd International Conference on Cancer Health Disparities |
| 2023 | iSRS 2023 Student/Postdoc Travel Award, Society of Radiopharmaceutical Sciences |
| 2023 | Presentation Award, Metabolism in Cancer Symposium Poster Session, The University of Texas MD Anderson Cancer Center |
| 2023 | Student Travel Stipend, World Molecular Imaging Society |
| 2023 | Second Place Travel Scholarship, Diagnostic Imaging Trainee Research Symposium, The University of Texas MD Anderson Cancer Center |
| 2021 | Leadership in Equity and Diversity Award, Texas A&M University College of Science |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. The Suitability of Zr-89 and Tb-161 as a Theranostic Pair as Evaluated through Ex Vivo Biodistribution and Nuclear Imaging Studies in Mouse Models. Poster. 13th Annual Metabolism in Cancer Symposium. Houston, Texas, US.
- 2024. Evaluating the therapeutic capability of a mucin 13 (MUC13)-directed antibody labeled with dual beta and Auger electron-emitting 161Tb. Poster. Diagnostic Imaging Trainee Research Symposium. Houston, Texas, US.
- 2024. Evaluating the Therapeutic Capability of a Mucin 13 (MUC13)-Directed Antibody Labeled with Dual Beta and Auger Electron-Emitting 161Tb. Poster. Cancer Systems Imaging Retreat and Symposium. Galveston, Texas, US.
- 2023. Optimizing routine production of [C-11]HCN for PET tracer development and clinical trials. Poster. 12th Annual Metabolism in Cancer Symposium. Houston, Texas, US.
- 2023. Evaluating the radionuclide theranostic potential of a MUC13-targeting antibody in colorectal cancer. Conference. Cancer Systems Imaging Retreat and Symposium. Galveston, Texas, US.
- 2023. Targeting the glycoprotein MUC13 for potential radionuclide theranostic development in colorectal cancer. Conference. Diagnostic Imaging Trainee Research Symposium. Houston, Texas, US.
- 2022. A study in targeting epithelial carcinomas using a 89Zr-radiolabeled anti-MUC13 antibody. Poster. Cancer Systems Imaging Retreat and Symposium. Galveston, Texas, US.
Regional Presentations
- 2025. Computational Design of Chelation Strategies for Radiopharmaceutical Applications Using Texas Advanced Computing Center. Conference. TACCSTER 2025. Austin, Texas, US.
- 2025. Evaluation of mucin 13 expression as a target for radioimmunotherapy: One step closer to a radionuclide theranostic strategy for colorectal cancer. Conference. 3rd International Conference on Cancer Health Disparities. Mission, Texas, US.
- 2024. Glycoprotein-targeted radionuclide theranostic pair for CRC. Invited. Southwest Regional Meeting of the American Chemical Society. Waco, Texas, US.
- 2024. Assessment of Mucin 13 (MUC13) as an imaging target for guiding colorectal cancer treatment: A pathway towards theranostic development. Conference. 2nd International Conference on Cancer Health Disparities 2024. Mission, Texas, US.
- 2024. Glycloprotein-targeted radionuclide theranostic pair for CRC. Conference. ACS Southwest Regional Meeting 2024. Waco, Texas, US.
National Presentations
- 2026. Glycoprotein mucin 13 expression as a radionuclide theranostic target in colorectal cancer. Conference. SNMMI Annual Meeting 2026. Reston, Virginia, US.
- 2026. Breaking Barriers: Tight Junction-Directed Radiotheranostic Probes for Metastatic Colorectal Cancer. Poster. SNMMI Annual Meeting 2026. Los Angeles, California, US.
- 2025. From patient data to probe: discovery of radiotheranostic target in metastatic colorectal cancer. Conference. World Molecular Imaging Congress 2025. Anchorage, Alaska, US.
- 2025. In vitro microdosimetry analysis of terbium-161 (161Tb)-labeled mucin-13-directed antibody suitable for radionuclide theranostics against colorectal cancer. Conference. World Molecular Imaging Congress 2025. Anchorage, Alaska, US.
- 2025. Multi-dose 161Tb radioimmunotherapy for improved outcome in MUC13-expressing xenograft mouse models of colorectal cancer. Poster. World Molecular Imaging Congress 2025. Anchorage, Alaska, US.
- 2023. Evaluating the radionuclide theranostic potential of a MUC13-targeting antibody in colorectal cancer, International Symposium on Radiopharmaceutical Sciences. Poster. International Symposium on Radiopharmaceutical Sciences 2023. Honolulu, Hawaii, US.
- 2022. Evaluation of MUC13 as a potential theranostic target for colorectal cancer using radioimmuno-PET imaging in a cell line-derived xenograft mouse model, World Molecular Imaging Congress. Poster. World Molecular Imaging Congress 2022. Miami, Florida, US.
- 2020. Spectroscopic and photochemical studies of a rare thiolate-bridged Rh2(II,II) complex lacking a metal-metal bond and exhibiting reversible redox events. Conference. American Chemical Society Fall 2020 Virtual Meeting & Exposition 2020, US.
International Presentations
- 2025. Preclinical evaluation of Mucin-13 targeted radionuclide theranostics approach suitable for metastatic colorectal cancer. Poster. 26th International Symposium on Radiopharmaceutical Sciences. Gold Coast, AU.
- 2024. Mucin 13 (MUC13) as an imaging target for radioimmuno-PET: Towards development of a theranostic strategy for colorectal cancer treatment. Poster. 7th Theranostics World Congress 2024. Santiago, CL.
- 2024. The suitability of 89Zr and 161Tb as a theranostic pair as evaluated through ex vivo biodistribution and nuclear imaging studies in mouse models. Poster. World Molecular Imaging Congress 2024. Montreal, CA.
- 2024. Potential of MUC13 as a target for radionuclide theranostics approach suitable for metastatic colorectal cancer. Poster. The 18th Annual Meeting of the Japanese Society for Molecular Imaging. Tokyo, JP.
- 2023. Optimizing routine production of [C-11]HCN for PET tracer development and clinical trials. Poster. World Molecular Imaging Congress 2023. Prague, CZ.
- 2023. Potential of MUC13 as a target for radionuclide theranostics—Comprehensive molecular profiling in well-annotated human colon cancer specimens. Poster. World Molecular Imaging Congress 2023. Prague, CZ.
Grant & Contract Support
| Date: | 2027 - 2029 |
| Title: | Improving radionuclide therapeutic efficacy through inhibition of pathways contributing to radioresistance |
| Funding Source: | NCI |
| Role: | Co-PI |
| ID: | R21CA312873 |
| Date: | 2026 - 2029 |
| Title: | MUC13 Targeted Theranostics for Colorectal Cancer |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP270227 |
| Date: | 2026 - 2027 |
| Title: | Metabolic Sensitization of MUC13-Directed Terbium-161 Therapy in Pancreatic Ductal Adenocarcinoma |
| Funding Source: | Project Purple Inc |
| Role: | Co-I |
| ID: | N/A |
| Date: | 2026 - 2029 |
| Title: | RADTACs: A Novel Platform for Proximity-Based Radiopharmaceutical Therapy |
| Funding Source: | American Association For Cancer Research |
| Role: | Co-I |
| ID: | FP00030480 |
| Date: | 2026 - 2029 |
| Title: | RADTAC: A Subcellularly Targeted CD70 Radiotheranostic Platform to Overcome Therapeutic Resistance in Renal Cell Carcinoma |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Co-I |
| ID: | N/A |
| Date: | 2026 - 2031 |
| Title: | Innovative Organometallic Complexes to Stably Harness Auger- and Alpha-Emitting Radioisotopes |
| Funding Source: | Welch Foundation |
| Role: | Key |
| ID: | 1685108 |
| Date: | 2025 - 2029 |
| Title: | Single-use Microfluidic Device for Radiopharmaceutical Production |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01EB034665 |
| Date: | 2024 - 2025 |
| Title: | Radionuclide Theranostic for BRAF-mutated CRC |
| Funding Source: | Colorectal Cancer Alliance |
| Role: | Co-I |
| Date: | 2020 - 2026 |
| Title: | CPRIT Recruitment – Established Investigator |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RR200046 |
Selected Publications
Peer-Reviewed Articles
- Yamaguchi A, Coll RP, Wang J, Bae SW, Tran HH, Huang B, Mashimo T, Schuler FW, Lin SJH, Sharma S, Dhakshinamoorthy S, Ta RT, Georgiou DK, Karacosta LG, Malik S, Khan S, Yallapu MM, Kopetz S, Chauhan SC, Manning HC. Glycoprotein mucin 13 expression as a theranostic target in colorectal cancer. Clin Cancer Res, 2026. e-Pub 2026. PMID: 42149121.
- Sharma S, Wen X, Wang J, Huang B, Hernandez D, Pham CD, Liu Z, Lin SJ, Yamaguchi A, Georgiou DK, Coll RP, Manning HC. Preclinical Fluorescence-Guided Imaging Leveraging Surrounding Sentinel Tumor Microenvironment Identifies High-Risk Premalignant Pancreatic Lesions. Clin Cancer Res 31(21):4475-4484, 2025. e-Pub 2025. PMID: 40853902.
- Coll RP, Dunbar KR. Three Reversible Redox States of Thiolate-Bridged Dirhodium Complexes without Metal-Metal Bonds. J Am Chem Soc 142(38):16313-16323, 2020. e-Pub 2020. PMID: 32790995.
- Coll RP, Tran H, Manning HC. Nuclear-Delivered Auger Emission using a Tb-155 Labeled Antibody.
- Strangis SR, Paolillo V, Coll RP, Ta RT, Manning HC. Optimizing routine production of [C-11]HCN for PET tracer development and clinical trials.
- McVeigh M, Coll RP, Manning HC, Bellan LM. Improvements in the Design of a Microfluidic Chip for Radiopharmaceutical Preparation.
- Coll RP, McVeigh M, Bellan LM, Manning HC. A Microfluidic Platform for Labeling Antibodies with Zr-89.
- Coll RP, Manning HC, Bright SJ. Radiosensitization of pancreatic cancer cells through disruption of glutamine transport with V-9302.
Review Articles
- Ward TE, Coll RP, Manning HC. The Consideration of Charge-Shift Bonding for the Incorporation of Emerging Radionuclides in Pharmaceutical Design. e-Pub 2026.
- Coll RP, Bright SJ, Martinus DKJ, Georgiou DK, Sawakuchi GO, Manning HC. Alpha particle-emitting radiopharmaceuticals as cancer therapy: biological basis, current status, and future outlook for therapeutics discovery. Mol Imaging Biol 25:991-1019, 2023. e-Pub 2023. PMID: 37845582.
- Lin M, Coll RP, Cohen AS, Georgiou DK, Manning HC. PET oncological radiopharmaceuticals: current status and perspectives. Molecules 27:6790, 2022. e-Pub 2022. PMID: 36296381.
Editorials
- Krebs S, Baird L, Pirovano G, Yamaguchi A, Coll RP, Lee JT, Carroll LS, Pomper MG, Manning. Today's Research, Tomorrow's Practice - White Paper from the Translation of New Therapy (TNT) Radiotheranostics Kick-off Pre-meeting of the Annual World Molecular Imaging Conference 2024. Mol Imaging Biol 27(6):877-882, 2025. PMID: 40971127.
Abstracts
- Saha S, Coll RP, Fillman K, Pellois JP, Turro C, Dunbar KR. Photoreleasing caged molecules containing nitrile functionality from Ru(II) complexes of the bulky 6-phenyl-2,2’-bipyridine ligand. 253rd American Chemical Society National Meeting & Exposition, 2017. e-Pub 2017.
Patient Reviews
CV information above last modified July 22, 2026